메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Next-Gen Omega-3 Solution: infinityseek Unveils Revolutionary…

[ 메디채널 김갑성 기자 ] Highlighting advances in vascular aging research and microalgae-based Omega-3 innovation SINGAPORE, Dec. 17, 2025 -- The 5th World Biological Science and Technology Conference 2025 Singapore (BioST 2025 SG) opened in Singapore, bringing together leading researchers and industry experts from the global biotechnology sector. The pioneer longevity brand infinityseek was invited to participate in the event, where it formally unveiled its groundbreaking anti-aging solution. The brand's research on vascular aging mechanisms drew strong interest from conference partic
- 김갑성 기자
- 2025-12-17 14:47
BioTec Sets New Market Standards with Fusion-Based Bio So…

SEOUL, South Korea, Dec. 17, 2025 -- BioTec's new releases are attracting attention as technology-fusion solutions rarely seen in the current market. The company's supplement developed with processed sulfur and microbial fermentation offers improved gut health and immune support for livestock and companion animals. Meanwhile, the ORP-reducing antioxidant salt provides differentiated functional benefits compared to standard refined salt, introducing a new paradigm in the functional food market. One of the key advantages of these solutions is their ability to integrate seamlessly into ex
- 김갑성 기자
- 2025-12-17 12:10
ASG Receives U.S. FDA IND Approval to Initiate Phase 1 Clinical Tri…

TAIPEI, Dec. 17, 2025 -- Asia Scientific Global Inc. (ASG), a leader in the research and development of novel inhaled drugs, today announced that its lead product, Beta1, has received Investigational New Drug (IND) application clearance from the U.S. Food and Drug Administration (FDA). Beta1 is currently the only inhaled investigational therapy for male erectile dysfunction to have received such approval and prepared to enter clinical trial. The FDA's clearance underscores ASG's capabilities in drug development and manufacturing technologies. ASG plans to initiate a Phase 1 clinical trial in
- 김갑성 기자
- 2025-12-17 11:30
Antengene Expands XPOVIO® Indications in Malaysia with Ap…

SHANGHAI and HONG KONG, Dec. 17, 2025 -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application (sNDA) for XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory diffuse l
- 김갑성 기자
- 2025-12-17 09:00
Aussie medtech Ferronova raises another $6 million to adva…

ADELAIDE, Australia, Dec. 17, 2025 -- Australian company Ferronova has raised a further $6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solution seeking to improve identification of cancer cells and reduce the risk of undetected recurrence following surgery. Ferronova's super-paramagnetic iron oxide nanoparticles bind to cells found in lymph nodes which aim to enable identification of tissue that could contain cancerous cells. The technology aims to support more informed surgical decision-making and address the problem that cancer cells are oft
- 김갑성 기자
- 2025-12-17 08:30
Harbour BioMed Enters into Global Strategic Collaboration an…

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, Dec. 17, 2025 -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a multi-year, global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multi-specific antibodies. Under the terms of the agreement, Harbour BioMed will collaborate with Bristol Myers Squibb to advance and accelerate multi-specific antibody discovery pro
- 김갑성 기자
- 2025-12-17 08:04
Jiaying Pharmaceutical: A New Pathway for the Industrializatio…

HONG KONG, Dec. 17, 2025 -- Recently, Meizhou in Guangdong, known as the "World Capital of the Hakka", welcomed a globally watched event, the Seventh World Hakka Entrepreneurs Convention. At this gathering that drew the attention of Hakka entrepreneurs worldwide, Guangdong Jiaying Pharmaceutical Co., Ltd. made a brilliant appearance with its star products, including Double-ingredient Throat Wind Relief Powder, Solid Essence Ginseng and Antler Pill, and Borneol Ointment, showcasing to the world the unique charm of Hakka medicine. Amid the wave of globalization, traditional Chi
- 김갑성 기자
- 2025-12-17 08:00
Leaders Dental Unveils Vision to Become "The Central Hub o…

SEOUL, South Korea, Dec. 17, 2025 -- Leaders Dental Laboratory, a leading force in Korea's digital dental technology sector, has announced a new vision to position itself as "the central hub of the digital dentistry ecosystem." To realize this vision, the company is making significant investments in AI-CAD, 3D printing, and IoT-based production automation. With the Korean implant market approaching saturation, Leaders Dental aims to secure long-term competitiveness by investing aggressively in next-generation technologies and expanding its reach beyond the domestic market into the g
- 김갑성 기자
- 2025-12-17 06:00
All CONEC Signs MOU with MINIMAX, Taking First Step in Standardiz…

SEOUL, South Korea, Dec. 17, 2025 -- All CONEC has signed a memorandum of understanding (MOU) with Australian digital dental company MINIMAX to establish a collaborative framework for digital implant production and lay the groundwork for overseas market entry. Digital implant production faces challenges due to differences in national product standards, production protocols, and communication methods. This partnership allows All CONEC to establish platform-based production standards at an early stage. The collaboration covers validating implant guide and prosthetic production pro
- 김갑성 기자
- 2025-12-17 06:00
The World's First AI Orchestrator Data Platform for Healthcare La…

[ 메디채널 김갑성 기자 ] Orchestral – a Pioneering AI Orchestrator Data Platform Built for Healthcare AUCKLAND, New Zealand, Dec. 17, 2025 -- McCrae Tech has launched the world's first health AI orchestrator. The product, called Orchestral, is a health-native AI orchestrator data platform. It seamlessly connects diverse data sources with AI agents, workflows, and algorithms – enabling scalable, governed AI deployment across healthcare systems. "Most information technology in healthcare falls into two camps: either a big, dumb bucket of cloud data or isolated pockets of AI
- 김갑성 기자
- 2025-12-17 02:00

이전

31 32 33 34 35 36 37 38 39 40

많이 본 기사

최근기사

2026-01-31_SAT

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2026년 01월 31일 17시 40분